X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
human necessities (284) 284
hygiene (284) 284
medical or veterinary science (284) 284
preparations for medical, dental, or toilet purposes (283) 283
specific therapeutic activity of chemical compounds ormedicinal preparations (191) 191
humans (38) 38
index medicus (34) 34
male (34) 34
female (33) 33
adult (31) 31
middle aged (29) 29
ribavirin (25) 25
drug therapy, combination (21) 21
ritonavir (21) 21
antiviral agents (19) 19
pharmacology & pharmacy (19) 19
uracil - analogs & derivatives (19) 19
abt-450/r-ombitasvir (18) 18
hepatitis c, chronic - drug therapy (18) 18
aged (16) 16
hepacivirus - genetics (16) 16
ritonavir - administration & dosage (16) 16
hcv (15) 15
hepatitis c virus (15) 15
gastroenterology and hepatology (14) 14
hepatitis c (14) 14
hiv infections - drug therapy (13) 13
ritonavir - therapeutic use (13) 13
therapy (13) 13
antiviral agents - therapeutic use (12) 12
calculating (12) 12
computing (12) 12
counting (12) 12
electric digital data processing (12) 12
genotype (12) 12
physics (12) 12
ritonavir - pharmacokinetics (12) 12
antiviral agents - adverse effects (11) 11
drug therapy (11) 11
genetic aspects (11) 11
hepatitis (11) 11
infectious diseases (11) 11
information and communication technology [ict] specially adaptedfor specific application fields (11) 11
interferon (11) 11
lopinavir (11) 11
macrocyclic compounds - administration & dosage (11) 11
ritonavir - adverse effects (11) 11
viral load (11) 11
young adult (11) 11
abridged index medicus (10) 10
anilides - administration & dosage (10) 10
anilides - adverse effects (10) 10
anilides - therapeutic use (10) 10
antiviral agents - administration & dosage (10) 10
antiviral agents - pharmacokinetics (10) 10
carbamates - administration & dosage (10) 10
carbamates - adverse effects (10) 10
carbamates - therapeutic use (10) 10
care and treatment (10) 10
dosage and administration (10) 10
drug interactions (10) 10
macrocyclic compounds - adverse effects (10) 10
macrocyclic compounds - therapeutic use (10) 10
pharmacokinetics (10) 10
ribavirin - therapeutic use (10) 10
sulfonamides - administration & dosage (10) 10
uracil - administration & dosage (10) 10
anilides - pharmacokinetics (9) 9
carbamates - pharmacokinetics (9) 9
clinical trials (9) 9
macrocyclic compounds - pharmacokinetics (9) 9
sulfonamides - pharmacokinetics (9) 9
trial (9) 9
adolescent (8) 8
drug administration schedule (8) 8
health aspects (8) 8
hepacivirus - drug effects (8) 8
hepatitis c, chronic - virology (8) 8
medicine, general & internal (8) 8
microbiology (8) 8
research (8) 8
ribavirin - adverse effects (8) 8
sulfonamides - adverse effects (8) 8
sulfonamides - therapeutic use (8) 8
treatment outcome (8) 8
uracil - pharmacokinetics (8) 8
analysis (7) 7
cirrhosis (7) 7
genotype & phenotype (7) 7
immunology (7) 7
uracil - adverse effects (7) 7
uracil - therapeutic use (7) 7
chronic hepatitis-c (6) 6
drug combinations (6) 6
gastroenterology & hepatology (6) 6
hiv-1 - drug effects (6) 6
infection (6) 6
patients (6) 6
pyrimidinones - administration & dosage (6) 6
regimen (6) 6
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (288) 288
French (51) 51
Spanish (42) 42
German (28) 28
Chinese (27) 27
Portuguese (13) 13
Danish (4) 4
Swedish (4) 4
Japanese (3) 3
Korean (3) 3
Polish (3) 3
Croatian (2) 2
Hungarian (2) 2
Lithuanian (2) 2
Serbian (2) 2
Slovenian (2) 2
Greek (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 21, pp. 1973 - 1982
In patients with HCV genotype 1 infection and cirrhosis, the rate of sustained virologic response was 92% with three new antiviral agents plus ribavirin for 12... 
SUSTAINED VIROLOGICAL RESPONSE | ALL-CAUSE MORTALITY | UNITED-STATES | MEDICINE, GENERAL & INTERNAL | VIRUS-INFECTION | TELAPREVIR | THERAPY | GENOTYPE 1 INFECTION | BOCEPREVIR | HCV INFECTION | EPIDEMIOLOGY | Recurrence | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Drug Resistance, Viral | Hepacivirus - genetics | Male | Hepatitis C, Chronic - complications | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Liver Cirrhosis - drug therapy | Liver Cirrhosis - etiology | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Genotype | Logistic Models | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Complications and side effects | Evaluation | Care and treatment | Usage | Hepatitis C | Liver cirrhosis | Ribavirin | Headache | Antiviral agents | Ritonavir | Body weight | Fatigue | Infections | Nausea | Proteinase inhibitors | RNA polymerase | Patients | Cirrhosis | Liver cancer | Genotype & phenotype | Hepatitis | Hemoglobin | Interferon | Drug therapy | Genotypes | Index Medicus | Abridged Index Medicus | Cirrosi hepàtica | Inhibidors enzimàtics | Enzyme inhibitors | Hepatic cirrhosis
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 21, pp. 1983 - 1992
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 17, pp. 1594 - 1603
In this trial in previously untreated patients with HCV genotype 1 infection and no cirrhosis, high rates of sustained response were achieved with three new... 
TRIAL | MEDICINE, GENERAL & INTERNAL | PLUS SOFOSBUVIR | C VIRUS-INFECTION | GENOTYPE 1 INFECTION | DACLATASVIR | SIMEPREVIR TMC435 | HEPATITIS-C | INTERFERON-FREE | TREATMENT-NAIVE PATIENTS | PHASE 2B | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Viral Load | Young Adult | Ritonavir - adverse effects | Ritonavir - therapeutic use | Adult | Female | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Drug Combinations | Uracil - analogs & derivatives | Dosage and administration | Research | Drug therapy, Combination | Hepatitis C | Drug therapy | Ribavirin | Ritonavir | Body weight | Diarrhea | Infections | Nausea | Proteinase inhibitors | Pruritus | Drug resistance | Patients | Genotype & phenotype | Cirrhosis | Sleep disorders | Hepatitis | Asthenia | Hemoglobin | Interferon | Drug dosages | Genotypes
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 17, pp. 1604 - 1614
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2013, Volume 368, Issue 1, pp. 45 - 53
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2014, Volume 370, Issue 3, pp. 222 - 232
Journal Article
JAMA, ISSN 0098-7484, 03/2015, Volume 313, Issue 12, pp. 1223 - 1231
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2015, Volume 63, Issue 4, pp. 805 - 812
Background & Aims Paritaprevir, ombitasvir, and dasabuvir are direct-acting antivirals for treatment of chronic hepatitis C virus (HCV) infection. The aim of... 
Gastroenterology and Hepatology | Direct-acting antiviral agents | Ombitasvir | Chronic hepatitis C | Hepatic impairment | Ritonavir | Paritaprevir | Pharmacokinetics | Dasabuvir | ABT-450/R-OMBITASVIR | TRANSPORTER EXPRESSION | RIBAVIRIN | LIVER-DISEASE | GENOTYPE 1 | THERAPY | CIRRHOSIS | HCV | GASTROENTEROLOGY & HEPATOLOGY | Antiviral Agents - pharmacokinetics | Humans | Middle Aged | Cytochrome P-450 CYP3A Inhibitors - pharmacokinetics | Male | Anilides - pharmacokinetics | Carbamates - administration & dosage | Hepatitis C, Chronic - complications | Carbamates - pharmacokinetics | Dose-Response Relationship, Drug | Uracil - administration & dosage | Ribavirin - administration & dosage | Ribavirin - pharmacokinetics | Female | Drug Therapy, Combination | Liver Function Tests | Cytochrome P-450 CYP3A Inhibitors - administration & dosage | Ritonavir - administration & dosage | Macrocyclic Compounds - pharmacokinetics | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Hepatic Insufficiency - blood | Hepatitis C, Chronic - blood | Sulfonamides - pharmacokinetics | Ritonavir - pharmacokinetics | Anilides - administration & dosage | Macrocyclic Compounds - administration & dosage | Hepatic Insufficiency - etiology | Uracil - pharmacokinetics | Sulfonamides - administration & dosage | Uracil - analogs & derivatives | Antiviral agents | Safety and security measures | Hepatitis C virus | Hepatitis C
Journal Article
Gastroenterology, ISSN 0016-5085, 2014, Volume 147, Issue 2, pp. 359 - 365.e1
Background & Aims The interferon-free regimen of ABT-450 (a protease inhibitor), ritonavir, ombitasvir (an NS5A inhibitor), dasabuvir (a non-nucleoside... 
Gastroenterology and Hepatology | IFN | PEARL-II | Ribavirin-Free | Interferon-Free Therapy | PLUS RIBAVIRIN | ABT-450/R-OMBITASVIR | VIRUS-INFECTION | TELAPREVIR | SOFOSBUVIR | CHRONIC HEPATITIS-C | COMBINATION | TRIAL | CIRRHOSIS | BOCEPREVIR | GASTROENTEROLOGY & HEPATOLOGY | Anilides - therapeutic use | Puerto Rico | Hepatitis C - drug therapy | United States | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | RNA, Viral - blood | Viral Load | Ritonavir - adverse effects | Time Factors | Ritonavir - therapeutic use | Adult | Female | Drug Therapy, Combination | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Europe | Ribavirin - therapeutic use | Uracil - therapeutic use | Genotype | Treatment Outcome | Macrocyclic Compounds - adverse effects | Biomarkers - blood | Macrocyclic Compounds - therapeutic use | Hepatitis C - diagnosis | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Hepacivirus - growth & development | Aged | Carbamates - therapeutic use | Uracil - analogs & derivatives | Medical colleges | Care and treatment | Proteases | Ritonavir | Biological products industry | Genetic aspects | Biological response modifiers | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin
Journal Article
Gastroenterology, ISSN 0016-5085, 2016, Volume 150, Issue 7, pp. 1590 - 1598
Journal Article
Journal Article